[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368533-105":59,"doc-detail-368533-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","primary-care-physician-use-of-elastic-scattering-spectroscopy-on-skin-lesions-suggestive-of-skin-cancer","Primary Care Physician Use of Elastic Scattering Spectroscopy on Skin Lesions Suggestive of Skin Cancer","","Noninvasive elastic scattering spectroscopy with the algorithm-powered DermaSensor was evaluated for identifying melanoma and basal and squamous cell cancers in primary care. DERM-SUCCESS enrolled adult patients (Aug 17, 2020-Dec 9, 2021) in the US and Australia; primary care physicians suspected skin cancer, lesions were scanned by the device, and biopsy specimens underwent histopathologic review. Results showed high overall sensitivity (95.5%) and strong negative predictive value (96.6%), with low positive predictive value (16.6%) and limited specificity (20.7%).",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/primary-care-physician-use-of-elastic-scattering-spectroscopy-on-skin-lesions-suggestive-of-skin-cancer/368533/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/primary-care-physician-use-of-elastic-scattering-spectroscopy-on-skin-lesions-suggestive-of-skin-cancer/368533.png","ImageObject",300,407,{"name":92,"@type":93},"Quinn Holloway","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the DermaSensor and what was it tested to detect in primary care?","Question",{"text":112,"@type":113},"DermaSensor is an algorithm-powered device using elastic scattering spectroscopy. It was evaluated to detect melanoma and basal and squamous cell cancers in the primary care setting.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the DERM-SUCCESS study designed and where were patients enrolled?",{"text":117,"@type":113},"DERM-SUCCESS was a blinded, prospective, multicenter pivotal study. Adult patients were enrolled between August 17, 2020 and December 9, 2021 at clinics in the US and Australia.",{"name":119,"@type":110,"acceptedAnswer":120},"What diagnostic performance did the device achieve overall and for patients aged 40 and older?",{"text":121,"@type":113},"Overall device sensitivity was 95.5%, and for the FDA-approved age group (40+), sensitivity was 96.3%. Negative predictive value was 96.6%, while specificity was 20.7%.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},368533,1790258949,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336474466712,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Primary Care Physician Use of Elastic Scattering Spectroscopy on Skin Lesions Suggestive of Skin Cancer  \nJournal of Primary Care & Community Health Volume 16: 1–11 © The Author(s) 2025 Article reuse guidelines:  \n[sagepub.com/journals-permissions](sagepub.com/journals-permissions)[ ](sagepub.com/journals-permissions)[DOI: 10.1177/21501319251344423](DOI: 10.1177/21501319251344423)[ ](DOI: 10.1177/21501319251344423)[journals.sagepub.com/home/jpc](journals.sagepub.com/home/jpc)  \nStephen P. Merry 1, Ivana T. Croghan2, Kimberly A. Dukes3, Brian C. McCormick4, Gerard T. Considine5, Michelle J. Duvall 1, Curtis T. Thompson6, and David J. Leffell7  \nAbstract  \nObjectives: To evaluate the performance of noninvasive, elastic scattering spectroscopy, algorithm-powered device (DermaSensor) to detect melanoma and basal and squamous cell cancers in the primary care setting.  \nPatients & Methods: DERM-SUCCESS, a blinded, prospective, multicenter pivotal study, enrolled adult patients between August 17, 2020, and December 9, 2021, with lesions that their primary care physicians (PCPs) suspected of skin cancer at clinics in the US (n = 18) and Australia (n = 4). These lesions were assessed by PCPs and scanned with the DermaSensor device. Biopsy specimens were collected, and histopathologic analysis was performed by dermatopathologists. The diagnostic performance of the device, dermatopathologist discordance, and subgroup analyses of clinical interest were calculated.  \nResults: Of the 1579 skin lesions enrolled, dermatopathologic analysis identified 224 (14.2%) cancers. Device sensitivity was 95.5%(95% CI, 91.7%-97.6%) overall and 96.3%(92.9%-98.4%) for patients in the FDA-approved age group 40 years and older (90.2% for melanoma, 97.8% for basal cell carcinoma, and 97.7% for squamous cell carcinoma). Device specificity was 20.7%. The negative predictive value was 96.6%, and the positive predictive value was 16.6%(NNB 6). The device misclassified as “monitor” rather than “investigate further” 4 keratinocyte carcinomas and 4 melanomas in patients aged 40 years or older (n = 8, 0.5% of lesions, 3.7% of cancers biopsied).  \nConclusions: The DermaSensor device is an easy-to-use, point-of-care, hand-held skin cancer adjunctive diagnostic device with high sensitivity and NPV to help inform PCP decision-making about skin lesions suspicious for cancer that need further evaluation and those that may be monitored.  \nKeywords  \nbasal cell carcinoma, DermaSensor, elastic scattering spectroscopy, melanoma, primary care, skin cancer, squamous cell carcinoma  \nReceived: March 12, 2025; revised: April 28, 2025; accepted: April 29, 2025  \nIntroduction  \nThe incidence of basal cell carcinoma (BCC), squamous cell carcinoma (SCC) (collectively, keratinocyte carcinomas [KC]), and malignant melanoma is increasing worldwide. Skin cancer will be diagnosed in 1 of 5 Americans during their lifetime, making it the most common type of cancer in the US.1 In 2022, an estimated 5.4 million cases of KC were diagnosed in 3.3 million people, and an estimated 2500 to 15 000 patients died ofSCC.1-4 An estimated 99 780 new cases of invasive melanoma and 97 920 cases of  \nmelanoma in situ were diagnosed in 2022, and 7650 people died of melanoma.1 Most skin cancer is curable if diagnosed early, including KC, melanoma in situ, and nonulcerated malignant melanoma with a Breslow depth less than 1 mm.1  \nSkin biopsy and subsequent histopathologic analysis is the standard for skin cancer diagnoses.5 The number needed to biopsy (NNB) ratio of total biopsies to identify 1 histopathologic-confirmed skin cancer is commonly used to compare the diagnostic accuracy of providers who perform skin biopsy and is the inverse of positive predictive value (PPV) .6 Training and experience in dermatologic care  \nCreative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License ([https://creativecommons.org/licenses/by-n","cbCaibatyb78BGDA","https://ap.wps.com/l/cbCaibatyb78BGDA","pdf",1163962,11,"English","# Abstract\n## Objectives\n## Patients & Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What is the DermaSensor and what was it tested to detect in primary care?\",\"answer\":\"DermaSensor is an algorithm-powered device using elastic scattering spectroscopy. It was evaluated to detect melanoma and basal and squamous cell cancers in the primary care setting.\"},{\"question\":\"How was the DERM-SUCCESS study designed and where were patients enrolled?\",\"answer\":\"DERM-SUCCESS was a blinded, prospective, multicenter pivotal study. Adult patients were enrolled between August 17, 2020 and December 9, 2021 at clinics in the US and Australia.\"},{\"question\":\"What diagnostic performance did the device achieve overall and for patients aged 40 and older?\",\"answer\":\"Overall device sensitivity was 95.5%, and for the FDA-approved age group (40+), sensitivity was 96.3%. Negative predictive value was 96.6%, while specificity was 20.7%.\"}]","Primary Care Physician Use of Elastic Scattering Spectroscopy on Skin Lesions Suggestive of Skin Cancer | PDF",1790177397,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a7f41f4c3f9521d7bffefcfab15cc6d9.webp",983,1276,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ba17e5522102da9e991e55ad9b09e9ce.webp",982,1275,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cd6e20fe2e8d4a2d963f38f7be43d87f.webp",981,1273,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a64f3d712c3852eb95ec6a30a3f017c3.webp",980,1272]